How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
Viking Therapeutics' new contract is a game changer. Here's how much money it could bring in.
Viking has found a manufacturing partner, removing a key overhang on the stock.
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity drug VK2735.
Viking Therapeutics Is Ready For A Standalone Future
Viking Therapeutics announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. The deal covers a substantial supply of both the subcutaneous and oral VK2735. The probability of a buyout is not zero, but I believe it is now greatly reduced. And that is a good thing.
Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade)
The sell-off in unprofitable stocks has hit tech and growth sectors hard, with investors seeking safety in healthcare and consumer staples. Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity. VKTX's $900M cash reserves and sufficient liquidity mitigate near-term funding risks, crucial amid current market uncertainties and lack of partnerships.
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled.
Viking Therapeutics stock toppled Tuesday after the biotech company inked a $150 million manufacturing deal for its weight-loss drug, VK2735. The post Viking Therapeutics Just Inked A $150 Million Manufacturing Deal.
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.10, indicating a +1.46% shift from the previous trading day.
Viking Therapeutics, Inc. (VKTX) Ascends But Remains Behind Market: Some Facts to Note
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $28.87, denoting a +0.7% change from the preceding trading day.
Is Viking Therapeutics a Buy Right Now?
Viking Therapeutics (VKTX -3.01%) soared into the spotlight about a year ago when it delivered promising data on a drug candidate that aims to compete in an area of very high demand: weight loss. The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Should You Buy VKTX Stock Amid Renewed M&A Speculations?
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%.
